SCIENTIFIC REPORTS

OPEN

Galectin-3 released in response to traumatic brain injury acts as an alarmin orchestrating brain immune response and promoting neurodegeneration

Received: 15 July 2016
Accepted: 21 December 2016
Published: 27 January 2017

Ping Kei Yip^{1,*}, Alejandro Carrillo-Jimenez^{2,*}, Paul King¹, Anna Vilalta³, Koji Nomura³, Chi Cheng Chau¹, Alexander Michael Scott Egerton¹, Zhuo-Hao Liu^{1,4}, Ashray Jayaram Shetty¹, Jordi L. Tremoleda¹, Meirion Davies¹, Tomas Deierborg⁵, John V. Priestley¹, Guy Charles Brown³, Adina Teodora Michael-Titus¹, Jose Luis Venero² & Miguel Angel Burguillos^{1,†}

Traumatic brain injury (TBI) is currently a major cause of morbidity and poor quality of life in Western society, with an estimate of 2.5 million people affected per year in Europe, indicating the need for advances in TBI treatment. Within the first 24 h after TBI, several inflammatory response factors become upregulated, including the lectin galectin-3. In this study, using a controlled cortical impact (CCI) model of head injury, we show a large increase in the expression of galectin-3 in microglia and also an increase in the released form of galectin-3 in the cerebrospinal fluid (CSF) 24 h after head injury. We report that galectin-3 can bind to TLR-4, and that administration of a neutralizing antibody against galectin-3 decreases the expression of IL-1 β , IL-6, TNF α and NOS2 and promotes neuroprotection in the cortical and hippocampal cell populations after head injury. Long-term analysis demonstrated a significant neuroprotection in the cortical region in the galectin-3 knockout animals in response to TBI. These results suggest that following head trauma, released galectin-3 may act as an alarmin, binding, among other proteins, to TLR-4 and promoting inflammation and neuronal loss. Taking all together, galectin-3 emerges as a clinically relevant target for TBI therapy.

Traumatic brain injury (TBI) has become one of the main causes of death and disability in the Western world, where ~160,000 admissions to hospital were catalogued as head injury during the period 2013–14 in the UK (data obtained from the Headway brain injury association). TBI pathology results in a complex set of symptoms that may lead to long-term impaired cognitive function and dementia, Parkinson's disease, and amyotrophic lateral sclerosis¹. Prompt actions in both pre-hospital and early in-hospital stay are considered as key factors to decrease mortality and improve the patient's neurological outcome². Despite recent advances in the management of TBI, its consequences remain significant and often very disabling³.

TBI can be divided into several stages: (i) the primary injury (due to the initial impact, e.g. contusion of the brain); (ii) the secondary injury, characterized by the spread of cell loss, diffuse axonal damage and also a

¹Centre for Neuroscience and Trauma. Blizard Institute. Queen Mary University of London, E1 2AT London, United Kingdom. ²Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia, Universidad de Sevilla, and Instituto de Biomedicina de Sevilla-Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, 41012 Sevilla, Spain. ³Department of Biochemistry, University of Cambridge, Cambridge CB2 1QW, United Kingdom. ⁴Chang Gung Medical College and University, Chang Gung Memorial Hospital, Department of Neurosurgery, 5 Fu-Shin Street, Linkou, Taiwan. ⁵Experimental Neuroinflammation Laboratory, Department of Experimental Medical Science, Lund University, BMC B11, 221 84 Lund, Sweden. *These authors contributed equally to this work. †Present address: Cambridge Institute for Medical Research, University of Cambridge, Cambridge CB2 0XY, United Kingdom. Correspondence and requests for materials should be addressed to M.A.B. (email: m.burguillos@qmul.ac.uk)

multiphasic neuroinflammatory response and (iii) the stage characterized by attempted, but ineffective, regeneration and repair. Many of the current efforts to reduce the damage after head injury are focused on the events that occur during the secondary injury phase and in particular those regulating the neuroinflammatory response⁴. Although it is well established that the neuroinflammatory process plays an important role during TBI, it is still not clear how to modulate it in a manner that provides beneficial results^{4,5}. Recent studies that have focused on the inflammatory response after head injury, demonstrate that microglia/macrophages display a mixed phenotype as a result of the complex signalling environment instead of a well-defined “M1” or “M2” phenotype^{6–8}. Eventually, the M2-like phenotype turns into a more proinflammatory phenotype which increases the cortical and hippocampal neurodegeneration⁸.

Various therapies to treat TBI have been shown in experimental animal models to be effective when they are dosed before or soon after TBI⁹. This highlights the importance of the early events triggered after head injury, for TBI progression. One of the first defence mechanisms that is activated after head injury is the innate immune response. Activation of members of the Toll-like Receptor (TLR) family has been shown to play an important role in different CNS injuries or infections and during the progression of different neurodegenerative diseases¹⁰. The release of alarmins or damage-associated molecular pattern molecules (DAMPs) upon injury, activates pattern recognition receptors (PRRs), such as TLRs¹¹. Among the different TLR members, TLR-2 and TLR-4 have been shown to play a key role during the neuroinflammatory response in various experimental models for TBI^{12–18}. Therefore, finding treatments to decrease TLR-2 and TLR-4 activation would be therapeutically advantageous.

Galectins are a family of proteins that consist of 15 members with significant sequence similarity in their carbohydrate-recognition domain (CRD) with affinity towards β -galactosidases¹⁹. Galectin-3 has been shown to have different functions depending on cell type and cellular location. Galectin-3 can be found inside the nucleus and the cytosol, embedded in the plasma membrane²⁰ or released extracellularly upon exposure to certain stimuli such as lipopolysaccharide (LPS)^{21,22} or IFN γ ²³. Galectin-3 appears to function as a master regulator during the inflammatory response in neurodegenerative diseases. We have recently demonstrated that galectin-3 is released by activated microglia in response to proinflammatory stimuli and importantly, galectin-3 acts as an endogenous paracrine TLR4 ligand²². We also demonstrated that released galectin-3 is essential for the full microglial response upon LPS treatment, thus supporting a central role of this galectin in regulating brain immune response. Furthermore our previous studies showed that: (i) galectin-3 is involved in the proinflammatory response triggered by α -synuclein in microglial cells²⁴, a hallmark of Parkinson's disease pathophysiology, and (ii) mice lacking galectin-3 were more resistant to hippocampal degeneration in a model of global cerebral ischemia that mimics the brain damage caused by cardiac arrest²². Regarding the role of galectin-3 under conditions of brain trauma, several studies have demonstrated striking early increases in the expression of galectin-3 in different trauma models including spinal cord injury^{25–27} and also in experimental models of TBI^{28,29}. Interestingly, a recent study performed in 8 weeks post-contusion spinal cord injured mice, found galectin-3 as one of the most upregulated extracellular proteins³⁰, suggesting that galectin-3 plays also a role at later stages of the injury. Consequently, and given the important role of galectin-3 in regulating brain inflammation and neurodegeneration, studies aimed to elucidate the role of this galectin after TBI are encouraged. In this study, we focus on the role that galectin-3 plays during the early neuroinflammatory response driven by microglia cells after head injury.

Results

Galectin-3 is expressed mainly in microglia cells and released after cortical impact. We used a cortical contusion mouse model to investigate when and where galectin-3 is expressed after head injury. Total RNA was extracted from cortex and hippocampus to quantify galectin-3 levels (Fig. 1a). We found a clear induction of galectin-3 expression 24 h after impact on the ipsilateral site in both cortex and hippocampus, and the levels remained high thereafter, even 3 weeks later (data not shown). Although induction of galectin-3 could not be observed 2 h after head injury using qPCR, we found some high galectin-3 expressing cells by immunohistochemistry in both cortex and hippocampus (Supplementary Fig. S1). We also investigated whether galectin-3 is released into brain parenchyma after head injury. Consequently, we analysed the content of galectin-3 in cerebrospinal fluid (CSF) after head injury as compared to naïve animals and we observed a statistically significant increase in galectin-3 in the CSF 24 h after the impact (Fig. 1b). We then decided to study which cells were predominantly expressing galectin-3 24 h after the injury through an immunohistochemical colocalization analysis. We observed that the majority of cells highly expressing galectin-3 were Iba-1 positive cells (Fig. 1b and d). To confirm more specifically whether those Iba-1 positive cells expressing galectin-3 were microglia, we used the specific microglia marker TMEM119³¹. This analysis confirmed that microglia express galectin-3 under conditions of brain trauma (Supplementary Fig. S1). Astrocytes have been shown to be able to express high levels of galectin-3 five days post injury (dpi) in a stab wound-injured cerebral cortex³². However, the number of GFAP-labelled astrocytes expressing galectin-3 24 h after the contusion was very low (Supplementary Fig. S1). Interestingly, we could find a milder punctiform galectin-3 staining present in cells belonging to the pyramidal cell layer in the CA1 region on both the ipsilateral and contralateral sites 24 h after injury (Fig. 1d). We also observed punctiform galectin-3 containing cells in NeuN positive cells in the cortex (Supplementary Fig. S1). Neuronal expression of galectin-3 has already been described in cultures of mouse dorsal root ganglion (DRG) neurons³³ and also in the developing and adult CNS in a subset of DRG neurons in the spinal ganglia³⁴.

The hippocampal formation, which is organized into very well defined neuronal layers, is highly affected by head trauma, thus allowing the study of interactions between reactive microglia and neurodegenerative processes. Iba-1 immunohistochemistry clearly demonstrated the presence of reactive microglia (based on morphological features) in the ipsilateral and contralateral hippocampus (Fig. 1d), especially when compared to sham (craniotomy) controls. Strikingly, the expression of galectin-3 was restricted to the ipsilateral cortex and hippocampus (compare TBI ipsilateral side *versus* contralateral side in Fig. 1c and d). Most galectin-3 expressing cells were iba-1 positive (Fig. 1c and d). Interestingly, these galectin-3 positive cells were consistently present in the degenerating

Figure 1. Galectin-3 is highly expressed and released in the brain after TBI in a cortical contusion murine model. qRT-PCR analysis of galectin-3 expression at 2 and 24h after TBI in the cortex and hippocampus (a). CSF protein levels of galectin-3 at 2 and 24 hours after TBI (b). Images showing colocalization of galectin-3 positive cells with Iba-1 in sham, TBI contralateral and TBI ipsilateral in Cortex (c) and Hippocampus (d) 24h after TBI. Statistics and error bars: mean $\pm$ s.d. $n = 4$ for A and $n = 5$ for B. Data were analyzed using a two-sided Student's t-test. * $p < 0.05$, *** $p < 0.001$ and **** $p < 0.0001$. Scales bar for c is 100 μ m and for d is 50 μ m. Arrowheads define the area of neuronal cell bodies in the CA1 region. Hoechst was used to counterstain the nuclei.

ipsilateral hippocampal neuronal cell layers (see the high number of expressing cells invading the ipsilateral CA1 area in Fig. 1d compared with the contralateral side).

Interestingly, some of the Iba-1 positive cells were apparently surrounding other cells within the CA1 region (see detail in Fig. 1d). Microglia can remove dead, dying and stressed neurons in a process termed phagocytosis³⁵. Since galectin-3 is released after trauma, and the phagocytic microglial receptor MerTK has been shown to bind galectin-3 acting as an opsonin³⁵ we wondered if exogenous galectin-3 participates in the phagocytic response

driven by microglia cells. To test our hypothesis, we pre-treated a murine microglial cell line (BV2) with recombinant galectin-3 for 18 h to assess the effect on the phagocytic response towards neuronal debris. We observed a remarkable 4-fold increase in the phagocytic capacity of BV2 cells in those cells pre-treated with galectin-3 compared to control (Supplementary Fig. S1). We decided then to analyse the capacity of recombinant galectin-3 to induce neuronal loss in rat primary mixed glial cultures (85% neurons). We observed a decrease in neuronal survival after 96 h treatment with recombinant galectin-3 (Supplementary Fig. S1). These results demonstrate the involvement of galectin-3 in the microglial phagocytic response and support its potential role in primary phagocytosis or phagoptosis³⁵.

Recently, our group has demonstrated that the released form of galectin-3 may act as a TLR4 agonist inducing a proinflammatory response under ischemic conditions²². We wanted to know whether the released form of galectin-3 after contusion might play also a role as a TLR-4 ligand²². For this reason, we analysed the interaction between TLR4 and galectin-3 through an immunoprecipitation approach. Protein extracts obtained from naïve, 2 h and 24 h CCI-injured mice were immunoprecipitated overnight with a TLR-4 antibody. The immunoprecipitate was collected and run on a gel, and then transferred into a nitrocellulose membrane. After that, the membrane was immunoblotted with a specific galectin-3 antibody. The results showed an interaction between galectin-3 and TLR4 at 24 h but not at 2 h after injury (Fig. 2a, cropped blots, full-length blot is presented in Supplementary Fig. S2) in correspondence with the TBI-induced released levels of galectin-3 as measured in the CSF (Fig. 1b).

Galectin-3 neutralising antibodies reduce inflammation, microglial activation and neuronal loss after head injury.

To further study the role of the released form of galectin-3 during the inflammatory response, we injected into the contused cortex 0.5 µg of either neutralizing antibody against galectin-3 or control isotype antibody (total volume injected was 5 µl at a rate of 1 µl/min) 1 hour after the contusion. We assessed the effect of the neutralizing antibody on neuronal survival in the cortex and hippocampus and the inflammatory response 24 h after injury. Interestingly, we observed a neuroprotective effect of galectin-3 neutralizing antibody in the cortex and hippocampus 24 h after head injury (Fig. 2b,c). TBI triggers a very potent neuroinflammatory response which is responsible for many of the deleterious effects during secondary injury³⁶. Microglia and macrophages express both M1 and M2 markers early after injury, but with time, the transient upregulation of M2 markers is replaced by a more M1-like phenotype⁸. Consequently, we analysed the mRNA levels of key M1 and M2 markers in response to neutralizing or control isotype antibodies 24 h after brain trauma. Treatment with galectin-3 neutralizing antibody reduced the trauma-induced increases of the different proinflammatory markers IL-1β, IL-6 and NOS2 (Fig. 2d–f). In contrast, neutralizing antibodies failed to alter the trauma-induced mRNA expression of the M2 markers Ym-1, Arg-1 and TGF-β (Fig. 2g–i). It is well known that microglia activation is accompanied by graded morphological alterations; thus early-stage activation is characterized by increased ramification of cytoplasmic processes, cell size and enhanced Iba-1 expression. After that, it is followed by further thickening of processes and retraction of the finer ones and increased cell body size to end up with a complete retraction of cytoplasmic processes, thus acquiring amoeboid-shape morphology. We analysed the effect that the injection of the galectin-3 neutralizing antibody had on different microglia morphology features 24 h after head injury. The results showed that microglia in mice injected with the neutralizing antibody exhibited a less “amoeboid” morphology with higher numbers of secondary branches and triple and quadruple junction points as compared to microglia from animals treated with IgG isotype control antibody (Supplementary Fig. S3).

Genetic knockout of galectin-3 reduces neuronal loss after head injury and changes microglial morphology.

Galectin-3 can play diverse roles in the regulation of different processes such as proliferation, adhesion, migration, invasion, angiogenesis, apoptosis and inflammation^{37–39}. It is noteworthy that in some of these processes opposite effects have been reported (as for instance in the control of the inflammatory response)^{23,40}, due to a different location within the cell and/or posttranslational modification. We wanted to analyse the effect that depletion of galectin-3 could have over the neuronal population after head injury using galectin-3 knockout mice (Fig. 3a). We first decided to analyse the survival of the neuronal population by analysing the number of NeuN-positive cells in three different regions (Cortex, CA1 pyramidal cell layer and Dentate Gyrus -DG-) within the first 24 h after injury. The results showed that lack of galectin-3 is neuroprotective within the first 2 h in the cortical region (Fig. 3b), while in the case of the hippocampal area we needed to wait until 24 h to observe a neuroprotective effect in the CA1 and DG regions (Fig. 3c,d). Figure 3e shows representative images of the three different regions (cortex, CA1 pyramidal layer and DG) in wild type and galectin-3 knockout mice within 24 h after contusion. We wanted to know if this neuroprotective effect within the first 24 h was long-lasting. For that reason, we analysed using toluidine blue staining the area of loss in the cortex 21 days after injury (Fig. 3f,g) in wild type and galectin-3 knockout mice. We found that lack of galectin-3 protected against the long-term TBI-induced cortical damage, confirming the observed neuroprotective effect at earlier time points.

We analyzed the neuroinflammatory response through the expression of several factors responsible for inducing either a proinflammatory or a supportive environment (Fig. 4) in the cortex and hippocampus early after impact. Most remarkable effects were found in the M2 markers analysed. Specifically, galectin-3 deficiency further increased the trauma-induced mRNA up-regulation for arginase-1 (Arg-1) in the hippocampus at 24 h and of Ym-1 in the cortex at 2 h (Fig. 4d,e). We also analysed two key neurotrophins, BDNF and NGF. Interestingly, galectin-3 knockout animals exhibited significantly higher cortical mRNA levels of BDNF as compared with wild type animals after trauma (Fig. 4f), while NGF remained unaltered (Supplementary Fig. S4). Regarding the pro-inflammatory response, TBI did up-regulate all markers analyzed, including IL-1β, TNF-α and NOS-2 in the cortex and hippocampus in WT animals (Fig. 4a–c). Unexpectedly, galectin-3 deficiency exacerbated transiently the trauma-induced upregulation of all M1 markers in cortex 2 h after injury (Fig. 4a–c). This highlighted a discrepancy in the immune response to TBI between galectin-3 deficient mice and mice injected with anti-galectin-3

Figure 2. Effect on the inflammatory response and neuronal survival after TBI in mice injected with neutralising antibody against galectin-3 compared to isotype IgG control. Analysis of the binding of TLR-4 and galectin-3 in the whole tissue extract at different time points after immunoprecipitating with TLR-4 antibody (a) followed by incubation with TLR-4 antibody (a, upper panel) or with galectin-3 antibody (a, lower panel). Immunohistochemistry of NeuN (b) and quantification (c) in the cortex and hippocampus of mice injected with neutralising antibody against galectin-3 or isotype control. Quantification of the gene expression in whole tissue for IL-1 β (d), IL-6 (e), NOS-2 (f), Ym-1 (g), Arg-1 (h) and TGF- β (i). Statistics and error bars: mean $\pm$ s.d. n = 4 for c, n = 7 for (d–i). Data were analysed using two-sided Student's t-test. *p < 0.05. Scale bar in b is 250 μ m.

Figure 3. Effect of the lack of galectin-3 on the neuronal survival in cortex and hippocampus after TBI. Chart comparing the expression of galectin-3 between wild type and galectin-3 knockout mice in the ipsilateral cortex 24 h after injury (**a**). Comparison of NeuN-positive cells between wild type and galectin-3 knockout mice after TBI in the cortex (**b**), CA1 (**c**) and dentate gyrus (**d**). Representative pictures of NeuN in different regions (**e**). Representative image of toluidine blue staining in wild type and galectin-3 knockout mice (**f**) and quantification of the cortical tissue loss (**g**) 21 days after injury. Statistics and error bars: mean $\pm$ s.d. $n = 4$ for (**a–d**) and (**g**). Data were analysed using two-sided student's *t*-test. * $p < 0.05$ ** $p < 0.01$ and **** $p < 0.0001$. Scale bar in **e** is 100 μ m and for **f** is 1000 μ m.

neutralising antibody. This may be explained by the difference between a total constitutive genetic deficiency of galectin-3, affecting all cell types and compartments, versus a model using a neutralising antibody against galectin-3, affecting only extracellular galectin-3.

Rod microglia have been shown to play a role during the proinflammatory response in two different experimental models of head trauma^{41,42}. Consequently, we decided to analyse the number of rod microglia early after head trauma. We focused on two areas where the appearance of the rod microglial cells (CA1 and the somatosensory cortex) has been described after head trauma. We observed a decrease in the presence of rod microglia in

Figure 4. Assessment of the inflammatory response in wild type and galectin-3 knockout mice after TBI. Analysis of the gene expression on the ipsilateral side of the isolated cortex and hippocampus in wild type and galectin-3 knockout mice for IL-1 β (a), TNF- α (b) and NOS-2 (c), Arginase-1 (d), Ym1 (e) and BDNF (f). Statistics and error bars: mean $\pm$ s.d. $n = 5$. Data were analysed using a two-sided Student's t-test followed by one-way ANOVA with post-hoc Fisher's least significant difference (LSD). * $p < 0.05$ ** $p < 0.01$.

the galectin-3 knockout mice (Supplementary Fig. S4), and of microglia positioned along the axons of neurons (Supplementary Fig. S4).

Discussion

One of the major challenges in TBI research is to identify new therapies or molecules that improve the patient's neurological outcome after injury. The secondary injury occurring after TBI contributes to a worsening of the

neurological outcome in addition to the initial contusion. Identifying factors that regulate the TBI-induced neuroinflammatory response could generate candidates for therapies.

Soon after a head or spinal cord injury, the expression of several proteins related to the inflammatory response is upregulated, including the lectin galectin-3^{25–29}. The neuroinflammatory response triggered by TBI is believed to be a major determinant of the secondary cell death after brain trauma. We have previously demonstrated that reactive microglia release galectin-3, thus playing a major role in the microglial immune response during ischemia²². Our goal in this study was to investigate the role of galectin-3 during head injury, and whether there was any release of galectin-3 after TBI. The idea that there could be an increase in the released form of galectin-3 after head injury was suggested by different studies demonstrating an increase in the levels of galectin-3 in plasma after TBI^{43,44}. Interestingly in one of these studies, the authors found a positive correlation between the galectin-3 levels in human plasma and the Glasgow Coma Scale (GCS) scores⁴³. In our study, we found significant amounts of galectin-3 in the mouse CSF 24 h after injury. The blood brain barrier is highly disrupted immediately after head injury⁴⁵, therefore a substantial leakage of galectin-3 from the brain parenchyma into the CSF can be expected.

Our next goal was to identify which cell types express galectin-3. Confocal immunofluorescence using antibodies to TMEM119 (specific to microglia³¹), Iba-1 (microglia and macrophages), GFAP (astrocytes) and NeuN (neurons) along with galectin-3 antibodies led us to confirm that: (i) Iba-1 positive cells are the main cells expressing galectin-3, (ii) reactive microglia, as demonstrated by TMEM119 expression, have also high levels of galectin-3, (iii) the majority of astrocytes lack galectin-3 expression within the first 24 h after impact, and (iv) most neurons do not express galectin-3, but unexpectedly certain neuronal cell types cells do express galectin-3.

We investigated the role(s) that extracellular galectin-3 may play during TBI. We have recently described a new role for released galectin-3 as an endogenous ligand for TLR-4, triggering a TLR-4-dependant neuroinflammatory response²². In our TBI model we observed that galectin-3 binds to TLR-4. Importantly, TLR-4 activation has been shown to modulate the early neuroinflammatory response after head injury, and inhibition of TLR-4 promotes a better neurological outcome^{15–17}. By using a neutralizing antibody against galectin-3 we could observe a decrease in the expression of IL-1 β , IL-6 and NOS2 but no difference in any of the M2 markers upon head injury.

There are studies where galectin-3 has been described to act as opsonin/bridging molecule by simultaneously binding to Mer receptor tyrosine kinase (MerTK) and “eat-me” signals on neurons thereby stimulating phagocytosis^{35,46,47}. Hence, one or more roles for the extracellular galectin-3 could occur at the same time in our model. The possibility that released galectin-3 may have an important role in modulating phagocytosis is certainly attractive. Consistent with this view we observed the presence of highly expressing galectin-3 reactive microglia/macrophages close to hippocampal cells and restricted to the pyramidal cell layer, which is highly sensitive to brain trauma. To ascertain a potential role of galectin-3 in promoting phagocytosis, we conducted *in vitro* culture assays using the microglial cell line BV2 exposed to TAMRA-labelled neuronal debris and pre-treated with exogenous galectin-3. FACS analysis demonstrated a positive role of exogenous galectin-3 in promoting microglial phagocytosis of neuronal debris. We also found that exogenous galectin-3 increased cell death in primary mixed glial cultures. Since phagocytosis can be extended to viable neurons, a process known as primary phagocytosis or phagoptosis, the possibility that galectin-3 participates in this process is plausible. Our results suggest an involvement of galectin-3 during the phagocytic response after TBI, but still more in depth studies are required to confirm this hypothesis.

Once we established a potential role of galectin-3 in promoting phagocytosis and cell death, we next analysed the potential effect of galectin-3 gene deletion in mice subjected to contusion TBI. A significant protection of cortical and hippocampal neurons was found in animals lacking galectin-3 at early and late time points (21 days) supporting our hypothesis that galectin-3 plays a deleterious role early after head trauma conditions.

We and others have studied the immunomodulatory properties of galectin-3 towards the two opposite polarization states of microglia or macrophages^{21–24}. TBI induces a complex environment where a mixed inflammatory response (M1 and M2 phenotypes) develops early after injury^{6–8}. We observed a similar pattern in our own analysis of the inflammatory response. Consequently, we analysed the effect of galectin-3 gene deletion on different markers of microglia polarization including IL-1 β , TNF- α and NOS-2 (M1) and arginase-1 and Ym-1 (M2) in response to TBI. Unexpectedly, galectin-3 gene deletion failed to modify the trauma-induced proinflammatory response, thus contrasting with the anti-inflammatory effect of galectin-3 neutralizing antibodies. However, it should be stressed that the hippocampus exhibited a dramatic increase in classical M2 activation markers 24 h after trauma (i.e. arginase-1). The reason for this discrepancy may be a consequence of the plethora of functions of galectin-3 depending on where it is located within the cell (released, cytosolic or nuclear) and the cell type in which it is expressed^{20–23,32}. The disparity observed in terms of M1 markers in response to either galectin-3 deletion (intra and extracellular) or neutralizing antibodies (extracellular) highlights the complex galectin-3-dependent cellular interactions that regulate brain immune functions. Galectin-3 gene deletion decreased the number of “rod microglia” shortly after brain trauma, thus supporting a role of galectin-3 in the proinflammatory response to brain trauma. Our study demonstrates that galectin-3 could be working as an endogenous ligand for TLR4 24 h after brain trauma, at a time post-injury when galectin-3 mRNA and protein levels are high. These results suggest that galectin-3 might be, together with other DAMPs, responsible for the full activation of different immune cells via TLR activation within the first 24 h. Therapies aimed at modulating galectin-3 expression or availability within the first 24 h after injury might have a potentially positive effect on patients’ outcome at later time points (as was observed in the galectin-3 knockout mice 21 days after injury).

Overall, we conclude that galectin-3 acts as an alarmin under conditions of brain trauma, and induces a strong proinflammatory response, most likely through TLR4 activation, and might be involved also in the phagocytic response. Considering that the facilitation of M2 activation may be a promising strategy to promote tissue repair under conditions of brain trauma, pharmacological inhibition of galectin-3 deserves special attention. In support

of this view, galectin-3 gene deletion further exacerbated the trauma-induced M2 response in the hippocampus. Aside from exhibiting enhanced phagocytosis, the M2 phenotype is associated with the release of trophic factors. We decided to analyse the effect of brain trauma and galectin-3 gene deletion on the mRNA levels of NGF and BDNF. We did not find any differences in the levels of NGF but strikingly, the lack of galectin-3 markedly increased the cortical mRNA levels of BDNF in response to brain trauma, with no response in the hippocampus. BDNF can be synthesized not only in neurons but also in astrocytes⁴⁸ and microglia⁴⁹. We could not observe changes in BDNF expression in mice treated with neutralizing antibody against galectin-3 (data not shown), suggesting that only intracellular galectin-3 is responsible for changes in BDNF expression. At the time point at which BDNF was upregulated (24 h), the majority of cells expressing galectin-3 were either neurons or microglia but not astrocytes. This suggests that the source of BDNF is either neuronal and/or microglial but not astrocytic at the time examined.

BDNF is strongly up-regulated shortly after TBI in the hippocampus and cortex^{50,51} which supports a trophic role of this neurotrophin after neurotrauma conditions. Consistent with this view, several studies have demonstrated a beneficial effect of BDNF administration in different spinal cord injury models^{52–54}. Furthermore, small molecule BDNF mimetics which specifically bind and activate trkB receptors, have been shown to improve motor learning after TBI⁵⁴ and have neuroprotective effects in adult^{55,56} and newborn⁵⁷ mice after CCI. Our results suggest an inhibitory role of galectin-3 on BDNF expression after head injury and add new evidence supporting the potential of anti-galectin-3 therapy in TBI.

In conclusion, our study demonstrates that galectin-3 is expressed and released predominantly by microglial cells in response to TBI, thus acting as an alarmin. The detrimental role of galectin-3 early after TBI was corroborated using galectin-3 knock-out mice and neutralizing antibodies, which conferred neuroprotection in response to TBI. Once released, galectin-3 binds to and activates TLR4, thus inducing a proinflammatory response and perhaps also enhancing the phagocytic response. Our data also suggest an important role of galectin-3 in regulating the M2 polarization state and BDNF mRNA expression after TBI.

Methods

Animals. All experiments conducted in Seville were approved by The University of Seville Ethical Committee for Experimental Research and fulfilled the requirements for experimental animal research in accordance with the Guidelines of the European Union Council (86/609/EU) and the Spanish regulations (BOE 34/11370–421, 2013) for the use of laboratory animals. All the experiments performed in London were approved by the Queen Mary University of London Animal Welfare and Ethical Review Body and carried out under Licence from the UK Home Office in accordance with the United Kingdom Animals (Scientific Procedures) Act 1986 for the use of animals in research and Directive 2010/63/EU. All experiments performed in Cambridge were performed in accordance with the UK Animals (Scientific Procedures) Act (1986) and were approved by the Cambridge University local ethical committee.

10–12 week-old not littermate wild type and galectin-3 null mutant mice on the C57BL/6 background⁵⁸ were obtained from Dr. T. Deierborg from Lund University. 10–12 week old CD-1 (IRC) outbred mice were purchased from Charles River Laboratories. Animals were housed under a 12 h light/dark cycle with free access to food and water.

Genotyping. The genotype of *gal3*^{−/−} and *gal3*^{+/+} mice was determined by analysis of DNA extracted from the tails using a QuickExtractTM (Epicentre) and amplified with the MyTaqTM Red DNA Polymerase (Bioline). The PCR consisted of 94 °C for 1 min, then 35 cycles with denaturation at 95 °C for 15 sec, annealing at 58 °C for 15 sec, and elongation at 72 °C for 10 sec.

The primer sequences used were obtained from a previous study⁵⁹: galectin-3 common 5′-CAC GAA CGT TTG CTC TCT GG-3′; galectin-3^{−/−} 5′-GCT TTT CTG GAT TCA TCG ACT GTG G-3′ (product size on a gel: 384 bp) and galectin-3^{+/+} 5′-TGA AAT ACT TAC CGA AAA GCT GTC TGC-3′ (product size on a gel: 300 bp).

Surgery. Mice were anaesthetized with a mixture of ketamine (50 mg/kg) and medetomidine (10 mg/kg) intraperitoneally (i.p.) and given pre-emptively analgesia with buprenorphine (0.05 mg/kg) subcutaneously (s.c.). Once surgical anaesthesia was confirmed, mice were placed into a stereotaxic frame and secured with teeth bar and guinea pig ear bars. A midline incision was made to expose the skull and a 3.0 mm craniotomy was made over the right parietal bone (central point was at −2.0 mm bregma, 2.5 mm lateral) using a 0.5 mm diameter burr bit connected to a hand held dental drill. Care was ensured so that the dura mater was undisturbed during the drilling and the removal of the skull flap.

The contusion was carried out using the Hatteras PinPoint controlled cortical impactor (Hatteras Instruments, USA). Parameters used were: 3.0 m/s velocity, 100 ms dwell time, and 2.2 mm impact depth at 20° angle. Sham injury mice received a craniotomy only. After the injury, the skull bone flap was replaced, skin sutured and placed into a warm incubator (27–28 °C) to recover.

In another study, agents were administered intracerebrally at 1 h post injury (final volume 5 µl of either galectin-3 neutralising antibody or IgG isotype control during 5 minutes at a rate of 1 µl/min; the concentration of the antibodies was 0.1 µg/µl). After the TBI surgery, the animal was transferred to a post-operative chamber and kept warm during the 1 h period prior to the injection into the brain. Ten minutes prior to the intracerebral injection, a top up of anaesthesia was provided to ensure the mice were fully surgically anaesthetized. The mice were secured into a stereotaxic frame and once the injury site was revealed agents were injected similarly to previously described⁶⁰. Briefly, using a glass micropipette, 5 µl of agent was injected directly into the injury epicentre at a speed of 1 µl/min and depth of 1.5 mm, avoiding the hippocampus due to the swelling of the cortex. After injection, the glass micropipette was slowly withdrawn, the skull bone flap gently placed over the site, and the skin was sutured. Approximately 40 min after the last dose of the anaesthetic drug, antipamezole (Antisedan, 2 mg/kg, s.c.) and sterile saline (100 ml/kg, s.c.) was administered to reverse the anaesthetic effect and prevent dehydration,

respectively. Post-operative care involved daily weight monitoring and twice daily administration of buprenorphine (0.05 mg/kg, s.c.) until there was weight gain or when culled at a defined time point.

At different time-points after the surgery, mice were put under deep anaesthesia before transcardially perfused with 4% paraformaldehyde solution for immunohistochemistry analysis. Mice whose brains were used to extract RNA or proteins extracts were transcardially perfused with PBS and the brains were quickly dissected and fast frozen.

Cell culture. Murine microglial BV2 cell line (passage <30) was cultured as previously described²². Primary mixed neuronal/glial cultures were prepared from cerebella of postnatal day 5 to 7 Wistar rats (male and female). Neurons were plated at a density of 5×10^5 cells per well in a 24-well plate and medium was changed once 24 hours after the cells were seeded. The cell cultures were left for one week before treatment. The approximate composition of the mixed cultures is $85 \pm 5\%$ neurons, $7 \pm 3\%$ astrocytes, and $5 \pm 3\%$ microglia. For live-cell counts, cultures were incubated with the nuclear stains Hoechst 33342 (5 µg/ml) and propidium iodide (1 µg/ml); Alexa 488-tagged isolectin-B4 (1 µg/ml) was used to distinguish microglia. Healthy and apoptotic (chromatin-condensed) neurons were recognized by their distinct nuclear morphology, whereas propidium iodide-positive cells (indicating membrane permeabilization) were identified as necrotic. Cell densities were evaluated using a Leica DMI6000 CS microscope. Four microscopy fields per well were quantified (around 150–200 neurons per field in control conditions), and experiments were performed with three independent culture preparations.

Phagocytosis assay. Phagocytosis assays were performed as previously described⁶¹. Dead neurons and neuronal debris were obtained by scraping cells from live neuronal-glial culture (85% neurons), and then passing cells 10 times through a 0.4×13 mm needle. The resulting dead neurons and debris was stained with the succinimidyl ester of 5-carboxytetramethylrhodamine (TAMRA), and 30 µg of protein was added to BV2 microglia for 2 hours. Microglia were then washed, and the uptake of dead neurons and debris into microglia quantified by flow cytometer (Accuri C6 flow cytometer, BD) as the mean fluorescence in the red channel (FL3) per cell (10,000 cells analysed per well). Where indicated, BV-2 cells were treated ± 200 nM galectin-3 (Sigma catalogue number G-5170) for 18 hours prior to addition of neuronal debris into the culture medium.

Immunohistochemistry. Coronal sections between Bregma +0.50 to −4.04 were cut at 20 µm using a cryostat which contained the impact site and were thaw mounted onto gelatinised Superfrost Plus slides. Sections that correspond to injury epicentre and penumbra were subjected to antigen retrieval with antigen unmasking solution (H-3300, Vector Labs) at 95–100 °C for 20 min followed by another 20 min at room temperature. For those sections developed using the chromogen 3,3'-diaminobenzidine (DAB), there was an extra incubation step afterwards for 15 min in a solution of 3% H₂O₂ diluted in 100% methanol to quench the endogenous peroxidase activity. Thereafter, the sections were blocked at room temperature in PBS-0.1% Triton X-100 with 10% normal donkey serum (Jackson Labs, UK). Later on, the slides were incubated with the indicated primary antibodies specified in the Supplementary Table S1. Slides were washed 3 times with PBS, and then incubated with the appropriate secondary antibodies (Supplementary Table S2) followed by one-hour room temperature incubation with the Vectastain ABC kit (Vector laboratories, catalogue number PK-4000) for the immunohistochemistry developed with DAB. The peroxidase reaction was visualized using the DAB Peroxidase (HRP) Substrate Kit (with Nickel), 3,3'-diaminobenzidine (Vectashield) reaction for 2–5 min. For DAB immunohistochemistry we employed a NanoZoomer-XR Digital slide scanner (Hamamatsu, Japan).

For fluorescent immunostaining, the staining process of slides was similar to DAB staining, but fluorescent secondary antibodies were used (Supplementary Table S2). Hoechst was used to counterstain the nuclei. For the visualization and analysis of the immunofluorescence we used a Zeiss upright 710 confocal microscope with a Meta spectral head and a Leica epifluorescence microscope.

Immunohistochemistry data analysis. Cortical and hippocampal measurements of the cell death and neuroinflammatory response following cortical impact were performed on 3 different regions (0.263 mm² each region) in the ipsilateral cortex and in the different hippocampal subregions Cornu Ammonis 1 (CA1), and dentate gyrus (DG). Viable pyramidal neurons were identified as NeuN-positive cells with typical round homogeneous immunoreactivity; the microglial distribution was quantified using Iba-1 staining. The quantitative analysis was carried out by performing a manual assessment of viable neurons using a 20x objective. The final numbers were obtained by multiplying the number of NeuN positive cells counted by the area sampling fraction. Four coronal brain sections per animal were quantified at four different bregma levels (−1.06 mm, −1.46 mm, −2.10 mm and −2.46 mm), to give a total number of viable NeuN-positive cells. For quantification of rod microglia, a picture of a region of 1.1 mm² in the CA1 and the somatosensory cortex regions was taken. The total cell number of rod microglia, defined as Iba-1 positive cells with highly polarized processes, was manually quantified and normalized to the area of the region of interest.

RT-PCR analysis. Total RNA was extracted using the TRIzol reagent (Sigma Aldrich) following the manufacturer's instructions. Using the RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific, UK), 0.5 µg of the total RNA was transformed into cDNA. Quantitative RT-PCR was performed using the MESA BLUE SYBR® Assay (Eurogentec, UK) and primers listed in Supplementary Table S3. Results were calculated using the delta Ct method and represented as absolute values with arbitrary units.

Measurement of galectin-3 in the cerebrospinal fluid (CSF) in mice. Cerebrospinal fluid samples were obtained from the *cisterna magna* using an insulin syringe in deeply anaesthetised naïve, and at 2 and 24 h after head injury. Approximately 5 µl of CSF was obtained and fast frozen with dry ice and kept at −80 °C for

further analysis. The amount of galectin-3 released present in the CSF from 3 μ l samples was analyzed using the galectin-3 kit (Cat No. 12684, BG-Medicine, USA).

Immunoprecipitation. The physical interaction between galectin-3 and TLR-4 was determined by immunoprecipitation analysis of brain tissue. The amount of 2.5 mg protein per sample was immunoprecipitated. We followed the method previously described²². Cells are lysed after treatment, homogenized with one pulse of 30 s sonication, and pelleted by centrifugation in buffer containing 20 mM Tris-HCl, pH 7.5, 140 mM NaCl, 1% Triton X-100, 2 mM EDTA, 1 μ M p-aminophenylmethanesulfonyl fluoride hydrochloride, 50 mM NaF, and 10% glycerol. The supernatants are pre-cleared with Dynabeads (Thermo Fisher Scientific) for 4 h at 4 °C. Later on, the cleared supernatants are incubated with 2.5 μ g of anti-TLR4 antibody and normal rabbit IgG (R&D systems) as a negative control overnight. The next day, the lysates are incubated with Dynabeads for 4 h at 4 °C. The immunoprecipitate were washed four times with buffer containing 50 mM Tris-HCl, pH 7.5, 0.1% SDS, 1% NP-40, and 62.5 mM NaCl and subsequently dissolved in denaturing sample buffer. All cell extracts were processed for immunoblotting with a SDS-polyacrylamide gel electrophoresis as described in a 12% Acrylamide/Bis-acrylamide gel.

Image capture and analysis. The quantification of microglia morphology was performed using a specially written script for the ImageJ analysis program (ImageJ 1.50d, National Institutes of Health, Bethesda, Maryland), and incorporating the ImageJ plugin “AnalyzeSkeleton”. AnalyzeSkeleton counts branch points (junctions) and branch length in cells following skeletonization. A 163 $\times$ 102 μ m frame was placed over different areas of interest in the hippocampus. Twenty cells per treatment were analysed using the script, to quantify the number of secondary branches and single, triple and quadruple junctions.

Quantification of the cortical tissue loss. The macroscopic images of the coronal brain sections (between bregma +0.5 to −4.04) from 21 days post traumatic brain injury stained with toluidine blue, were captured on a digital eyepiece camera via a dissecting microscope. Briefly, sections were air dried and rinsed shortly in distilled water. After that, the slides were submerged in a solution of 300 ml of 70% EtOH with 5 ml of 0.2 M acetic acid for 2 hours. Thereafter, slides were incubated in a filtered 0.1% toluidine blue solution for 10 minutes and rinsed 3 times with 1 minute distilled water washes. Slides were dehydrated through a series of 2 minutes washes with increasing concentration of ethanol (1x with 70% EtOH, 2x with 96% EtOH and 3x with 99% EtOH). After a further 3 $\times$ 5 minutes incubation in 100% xylene, the slides were mounted using DPX mounting media. The brain images were taken from 3 slides per animal, each slide containing 4–5 sections. Images were analysed using ImageJ software. The region of brain tissue loss was drawn around in reference to the contralateral side of the brain section, and the area was converted to mm² based on measurements captured on a graticule. Statistical analysis was carried out using Student's t-test from n = 4 animals per group.

Statistical Analyses. The differences between control and experimental groups were evaluated with two sided-*t*-tests or one-way ANOVA with post-hoc Fisher's least significant difference (LSD) or Tukey's analysis (more than 2 groups) where appropriate, with *P* < 0.05 was considered statistically significant.

References

- Pearce, N., Gallo, V. & McElvenny, D. Head trauma in sport and neurodegenerative disease: an issue whose time has come? *Neurobiology of aging* **36**, 1383–1389, doi: 10.1016/j.neurobiolaging.2014.12.024 (2015).
- Brazinova, A. *et al.* Factors that may improve outcomes of early traumatic brain injury care: prospective multicenter study in Austria. *Scandinavian journal of trauma, resuscitation and emergency medicine* **23**, 53, doi: 10.1186/s13049-015-0133-z (2015).
- Das, M., Mohapatra, S. & Mohapatra, S. S. New perspectives on central and peripheral immune responses to acute traumatic brain injury. *Journal of neuroinflammation* **9**, 236, doi: 10.1186/1742-2094-9-236 (2012).
- Hellewell, S., Semple, B. D. & Morganti-Kossmann, M. C. Therapies negating neuroinflammation after brain trauma. *Brain research*, doi: 10.1016/j.brainres.2015.12.024 (2015).
- Kumar, A. & Loane, D. J. Neuroinflammation after traumatic brain injury: opportunities for therapeutic intervention. *Brain, behavior, and immunity* **26**, 1191–1201, doi: 10.1016/j.bbi.2012.06.008 (2012).
- Morganti, J. M., Riparip, L. K. & Rosi, S. Call Off the Dog(ma): M1/M2 Polarization Is Concurrent following Traumatic Brain Injury. *PloS one* **11**, e0148001, doi: 10.1371/journal.pone.0148001 (2016).
- Kim, C. C., Nakamura, M. C. & Hsieh, C. L. Brain trauma elicits non-canonical macrophage activation states. *Journal of neuroinflammation* **13**, 117, doi: 10.1186/s12974-016-0581-z (2016).
- Kumar, A., Alvarez-Croda, D. M., Stoica, B. A., Faden, A. I. & Loane, D. J. Microglial/Macrophage Polarization Dynamics following Traumatic Brain Injury. *Journal of neurotrauma*, doi: 10.1089/neu.2015.4268 (2015).
- Bergold, P. J. Treatment of traumatic brain injury with anti-inflammatory drugs. *Experimental neurology* **275** Pt 3, 367–380, doi: 10.1016/j.expneurol.2015.05.024 (2016).
- Hanamsagar, R., Hanke, M. L. & Kielian, T. Toll-like receptor (TLR) and inflammasome actions in the central nervous system. *Trends in immunology* **33**, 333–342, doi: 10.1016/j.it.2012.03.001 (2012).
- Chen, G. Y. & Nunez, G. Sterile inflammation: sensing and reacting to damage. *Nature reviews. Immunology* **10**, 826–837, doi: 10.1038/nri2873 (2010).
- Park, C. *et al.* Toll-like receptor 2 contributes to glial cell activation and heme oxygenase-1 expression in traumatic brain injury. *Neuroscience letters* **431**, 123–128, doi: 10.1016/j.neulet.2007.11.057 (2008).
- Hayward, J. H. & Lee, S. J. A Decade of Research on TLR2 Discovering Its Pivotal Role in Glial Activation and Neuroinflammation in Neurodegenerative Diseases. *Experimental neurobiology* **23**, 138–147, doi: 10.5607/en.2014.23.2.138 (2014).
- Yu, Z. Q. & Zha, J. H. Genetic ablation of toll-like receptor 2 reduces secondary brain injury caused by cortical contusion in mice. *Annals of clinical and laboratory science* **42**, 26–33 (2012).
- Ahmad, A. *et al.* Absence of TLR4 reduces neurovascular unit and secondary inflammatory process after traumatic brain injury in mice. *PloS one* **8**, e57208, doi: 10.1371/journal.pone.0057208 (2013).
- Zhang, D. *et al.* TLR4 inhibitor resatorvid provides neuroprotection in experimental traumatic brain injury: implication in the treatment of human brain injury. *Neurochemistry international* **75**, 11–18, doi: 10.1016/j.neuint.2014.05.003 (2014).
- Laird, M. D. *et al.* High mobility group box protein-1 promotes cerebral edema after traumatic brain injury via activation of toll-like receptor 4. *Glia* **62**, 26–38, doi: 10.1002/glia.22581 (2014).

18. Fang, H., Wang, P. F., Zhou, Y., Wang, Y. C. & Yang, Q. W. Toll-like receptor 4 signaling in intracerebral hemorrhage-induced inflammation and injury. *Journal of neuroinflammation* **10**, 27, doi: 10.1186/1742-2094-10-27 (2013).
19. Leffler, H., Carlsson, S., Hedlund, M., Qian, Y. & Poirier, F. Introduction to galectins. *Glycoconjugate journal* **19**, 433–440, doi: 10.1023/B:GLYC.0000014072.34840.04 (2004).
20. Funasaka, T., Raz, A. & Nangia-Makker, P. Galectin-3 in angiogenesis and metastasis. *Glycobiology* **24**, 886–891, doi: 10.1093/glycob/cwu086 (2014).
21. Li, Y. *et al.* Galectin-3 is a negative regulator of lipopolysaccharide-mediated inflammation. *Journal of immunology* **181**, 2781–2789 (2008).
22. Burguillos, M. A. *et al.* Microglia-Secreted Galectin-3 Acts as a Toll-like Receptor 4 Ligand and Contributes to Microglial Activation. *Cell reports*, doi: 10.1016/j.celrep.2015.02.012 (2015).
23. Jeon, S. B. *et al.* Galectin-3 exerts cytokine-like regulatory actions through the JAK-STAT pathway. *Journal of immunology* **185**, 7037–7046, doi: 10.4049/jimmunol.1000154 (2010).
24. Boza-Serrano, A. *et al.* The role of Galectin-3 in alpha-synuclein-induced microglial activation. *Acta neuropathologica communications* **2**, 156, doi: 10.1186/s40478-014-0156-0 (2014).
25. Pajoohesh-Ganji, A., Knobloch, S. M., Faden, A. I. & Byrnes, K. R. Characterization of inflammatory gene expression and galectin-3 function after spinal cord injury in mice. *Brain research* **1475**, 96–105, doi: 10.1016/j.brainres.2012.07.058 (2012).
26. Mostacada, K., Oliveira, F. L., Villa-Verde, D. M. & Martinez, A. M. Lack of galectin-3 improves the functional outcome and tissue sparing by modulating inflammatory response after a compressive spinal cord injury. *Experimental neurology* **271**, 390–400, doi: 10.1016/j.expneurol.2015.07.006 (2015).
27. Byrnes, K. R., Washington, P. M., Knobloch, S. M., Hoffman, E. & Faden, A. I. Delayed inflammatory mRNA and protein expression after spinal cord injury. *Journal of neuroinflammation* **8**, 130, doi: 10.1186/1742-2094-8-130 (2011).
28. Venkatesan, C., Chrzasczcz, M., Choi, N. & Wainwright, M. S. Chronic upregulation of activated microglia immunoreactive for galectin-3/Mac-2 and nerve growth factor following diffuse axonal injury. *Journal of neuroinflammation* **7**, 32, doi: 10.1186/1742-2094-7-32 (2010).
29. Natale, J. E., Ahmed, F., Cernak, I., Stoica, B. & Faden, A. I. Gene expression profile changes are commonly modulated across models and species after traumatic brain injury. *Journal of neurotrauma* **20**, 907–927, doi: 10.1089/089771503770195777 (2003).
30. Didangelos, A. *et al.* High-throughput proteomics reveal alarmins as amplifiers of tissue pathology and inflammation after spinal cord injury. *Scientific Reports* **6**, doi: 10.1038/srep21607 (2016).
31. Bennett, M. L. *et al.* New tools for studying microglia in the mouse and human CNS. *Proceedings of the National Academy of Sciences of the United States of America* **113**, E1738–1746, doi: 10.1073/pnas.1525528113 (2016).
32. Sirko, S. *et al.* Astrocyte reactivity after brain injury: The role of galectins 1 and 3. *Glia* **63**, 2340–2361, doi: 10.1002/glia.22898 (2015).
33. Pesheva, P., Kuklinski, S., Biersack, H. J. & Probstmeier, R. Nerve growth factor-mediated expression of galectin-3 in mouse dorsal root ganglion neurons. *Neuroscience letters* **293**, 37–40 (2000).
34. Dodd, J. & Jessell, T. M. Cell surface glycoconjugates and carbohydrate-binding proteins: possible recognition signals in sensory neurone development. *The Journal of experimental biology* **124**, 225–238 (1986).
35. Brown, G. C. & Neher, J. J. Microglial phagocytosis of live neurons. *Nature reviews. Neuroscience* **15**, 209–216, doi: 10.1038/nrn3710 (2014).
36. Corps, K. N., Roth, T. L. & McGavern, D. B. Inflammation and neuroprotection in traumatic brain injury. *JAMA neurology* **72**, 355–362, doi: 10.1001/jamaneurol.2014.3558 (2015).
37. Sundblad, V., Croci, D. O. & Rabinovich, G. A. Regulated expression of galectin-3, a multifunctional glycan-binding protein, in haematopoietic and non-haematopoietic tissues. *Histology and histopathology* **26**, 247–265 (2011).
38. Nowlaczyk, A. U. & Yu, L. G. Galectin-3—a jack-of-all-trades in cancer. *Cancer letters* **313**, 123–128, doi: 10.1016/j.canlet.2011.09.003 (2011).
39. Shin, T. The pleiotropic effects of galectin-3 in neuroinflammation: a review. *Acta histochemica* **115**, 407–411, doi: 10.1016/j.acthis.2012.11.010 (2013).
40. MacKinnon, A. C. *et al.* Regulation of alternative macrophage activation by galectin-3. *Journal of immunology* **180**, 2650–2658 (2008).
41. Ziebell, J. M., Taylor, S. E., Cao, T., Harrison, J. L. & Lifshitz, J. Rod microglia: elongation, alignment, and coupling to form trains across the somatosensory cortex after experimental diffuse brain injury. *Journal of neuroinflammation* **9**, 247, doi: 10.1186/1742-2094-9-247 (2012).
42. Taylor, S. E., Morganti-Kossmann, C., Lifshitz, J. & Ziebell, J. M. Rod microglia: a morphological definition. *PLoS one* **9**, e97096, doi: 10.1371/journal.pone.0097096 (2014).
43. Shen, Y. F. *et al.* The change of plasma galectin-3 concentrations after traumatic brain injury. *Clinica chimica acta; international journal of clinical chemistry* **456**, 75–80, doi: 10.1016/j.cca.2016.02.029 (2016).
44. Shan, R. *et al.* A New Panel of Blood Biomarkers for the Diagnosis of Mild Traumatic Brain Injury/Concussion in Adults. *Journal of neurotrauma* **33**, 49–57, doi: 10.1089/neu.2014.3811 (2016).
45. Alves, J. L. Blood-brain barrier and traumatic brain injury. *Journal of neuroscience research* **92**, 141–147, doi: 10.1002/jnr.23300 (2014).
46. Neher, J. J. *et al.* Phagocytosis executes delayed neuronal death after focal brain ischemia. *Proceedings of the National Academy of Sciences of the United States of America* **110**, E4098–4107, doi: 10.1073/pnas.1308679110 (2013).
47. Jha, M. K., Lee, W. H. & Suk, K. Functional polarization of neuroglia: Implications in neuroinflammation and neurological disorders. *Biochemical pharmacology* **103**, 1–16, doi: 10.1016/j.bcp.2015.11.003 (2016).
48. Parpura, V. & Zorec, R. Gliotransmission: Exocytotic release from astrocytes. *Brain research reviews* **63**, 83–92, doi: 10.1016/j.brainresrev.2009.11.008 (2010).
49. Ferrini, F. & De Koninck, Y. Microglia control neuronal network excitability via BDNF signalling. *Neural plasticity* **2013**, 429815, doi: 10.1155/2013/429815 (2013).
50. Hicks, R. R. *et al.* Alterations in BDNF and trkB mRNA levels in the cerebral cortex following experimental brain trauma in rats. *Journal of neurotrauma* **16**, 501–510, doi: 10.1089/neu.1999.16.501 (1999).
51. Hicks, R. R., Numan, S., Dhillon, H. S., Prasad, M. R. & Seroogy, K. B. Alterations in BDNF and NT-3 mRNAs in rat hippocampus after experimental brain trauma. *Brain research. Molecular brain research* **48**, 401–406 (1997).
52. Ji, X. C. *et al.* Local Injection of Lenti-BDNF at the Lesion Site Promotes M2 Macrophage Polarization and Inhibits Inflammatory Response After Spinal Cord Injury in Mice. *Cellular and molecular neurobiology* **35**, 881–890, doi: 10.1007/s10571-015-0182-x (2015).
53. Santos, D., Giudetti, G., Micera, S., Navarro, X. & Del Valle, J. Focal release of neurotrophic factors by biodegradable microspheres enhance motor and sensory axonal regeneration *in vitro* and *in vivo*. *Brain research* **1636**, 93–106, doi: 10.1016/j.brainres.2016.01.051 (2016).
54. Butenschon, J. *et al.* PSA-NCAM positive neural progenitors stably expressing BDNF promote functional recovery in a mouse model of spinal cord injury. *Stem cell research & therapy* **7**, 11, doi: 10.1186/s13287-015-0268-x (2016).
55. Massa, S. M. *et al.* Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. *The Journal of clinical investigation* **120**, 1774–1785, doi: 10.1172/JCI41356 (2010).

56. Wu, C. H. *et al.* Post-injury treatment with 7,8-dihydroxyflavone, a TrkB receptor agonist, protects against experimental traumatic brain injury via PI3K/Akt signaling. *PLoS one* **9**, e113397, doi: 10.1371/journal.pone.0113397 (2014).
57. Chen, L., Gao, X., Zhao, S., Hu, W. & Chen, J. The Small-Molecule TrkB Agonist 7, 8-Dihydroxyflavone Decreases Hippocampal Newborn Neuron Death After Traumatic Brain Injury. *Journal of neuropathology and experimental neurology* **74**, 557–567, doi: 10.1097/NEN.000000000000199 (2015).
58. Colnot, C., Fowles, D., Ripoche, M. A., Bouchaert, I. & Poirier, F. Embryonic implantation in galectin 1/galectin 3 double mutant mice. *Developmental dynamics: an official publication of the American Association of Anatomists* **211**, 306–313, doi: 10.1002/(SICI)1097-0177(199804)211:4<306::AID-AJA2>3.0.CO;2-L (1998).
59. Doverhag, C. *et al.* Galectin-3 contributes to neonatal hypoxic-ischemic brain injury. *Neurobiology of disease* **38**, 36–46, doi: 10.1016/j.nbd.2009.12.024 (2010).
60. Liu, Z.-H. *et al.* A Single Bolus of Docosahexaenoic Acid Promotes Neuroplastic Changes in the Innervation of Spinal Cord Interneurons and Motor Neurons and Improves Functional Recovery after Spinal Cord Injury. *Journal of Neuroscience* **35**(37), 12733–12752 (2015).
61. Fricker, M., Oliva-Martin, M. J. & Brown, G. C. Primary phagocytosis of viable neurons by microglia activated with LPS or Abeta is dependent on calreticulin/LRP phagocytic signalling. *Journal of Neuroinflammation* **9**, 196 (2012).

Acknowledgements

We thank Drs B. Joseph, D. Sheer and M. Branco for providing us with reagents. A.C.-J. is supported by a pre-doctoral fellowship from Spanish Ministerio de Educación, Cultura y Deporte. This work has been supported by grants from the Spanish Ministerio SAF2015–64171R (MINECO/FEDER, UE), Blizzard Research Theme grants, Blizzard Institute, Queen Mary University of London. M.A.B. has been funded by the Barts Charity Centre for Trauma Sciences (C4TS) and the Wellcome Trust Institutional Strategic Support Fund (ISSF).

Author Contributions

P.K.Y., A.C.-J. and M.A.B. performed all the experiments except otherwise noted. P.K., Z.-H.L., A.M.S.E., A.J.S., C.C.C., J.L.-T., and M.D. contributed with *in vivo* analyses. J.V.P. generated the ImageJ script employed in the morphology analysis. A.V., K.N. and G.C.B. were responsible for the phagocytic response and cell death analysis *in vitro*. A. M.-T., and T.D. were involved in study design. M.A.B. and J.L.V. designed the study, analysed and interpreted the data. M.A.B. and J.L.V. wrote the first draft of the manuscript. All authors discussed the results and commented on or edited the manuscript.

Additional Information

Supplementary information accompanies this paper at <http://www.nature.com/srep>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Yip, P. K. *et al.* Galectin-3 released in response to traumatic brain injury acts as an alarmin orchestrating brain immune response and promoting neurodegeneration. *Sci. Rep.* **7**, 41689; doi: 10.1038/srep41689 (2017).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2017